The vaccine for this population is usually AREXVY. Receiving your vaccine doesn’t only help you, it helps the people around you stay healthy as well. “You know, I always say that an ounce of ...
The Canadian Press on MSN4h
Health Canada approves Moderna's mRNA RSV vaccine, company saysModerna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback